Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
YD Bio Limited Ordinary Shares (YDES)
USD2.24
+0.12 (+5.66%)
TW NASDAQ Healthcare Biotechnology
Address
No. 3, Xingnan St. 115001
Taipei, TW
Taipei, TW
CEO
Ethan Shen
Website
ydesgroup.com
IPO
2025-08-29
CIK 2011674 ISIN KYG983011076
Also trades on
NASDAQ Global Select · YDES (USD)
NASDAQ Global Select · YDESW (USD)
Description
Breeze Holdings Acquisition Corp. is a clinical-stage biopharmaceutical company based in Taipei, Taiwan. The firm concentrates its efforts on developing medical diagnostics for cancer prevention and creating exosome-based therapeutics, both of which aim to revolutionize treatment options for diseases with significant unmet medical needs.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD2.24
+0.12 (+5.66%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
31.4K
Beta
-0.18
Float Shares
1.43M
Free Float %
2.0%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -8.26% | -31.49% | -36.86% | -62.47% | -72.07% | -73.58% | -73.26% | -73.26% | -73.26% | -73.26% | -73.26% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Price Targets & DCF
Current price
2.24
DCF (Unlevered)
0.12
-94.7%
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
Quality scores
Altman Z-Score
7.17
Safe zone
Piotroski F-Score
3 / 9
Average
MOAT Score
3 / 10
No MOAT
Composite Rating
D+
Overall Score
1 / 5
Low
DCF Score
1 / 5
Low
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
1 / 5
Low
P/E Score
1 / 5
Low
P/Book Score
1 / 5
Low
Operational MOAT
✗ Below peers
-
Revenue growth Biotechnology: +1.6%+16.9% ★
-
EPS growth Biotechnology: +29.7%+78.6% ★ Q2'25: -116.0% (vs Q2'24)
-
FCF margin FCF growth · Biotechnology: +16.2%-1,165.5%
-
EBIT margin Biotechnology: +0.0%-883.3%
-
ROIC Biotechnology: -16.1%— Q2'25: +100.0% (vs Q2'24)
-
Share dilution Biotechnology: -3.4%+1,509.3% Q2'25: -19.2% (vs Q2'24)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×0.00× Q2'25: 0.00× (vs Q2'24)
Valuation Multiples
From
To
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-28 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-27 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-26 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-22 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-21 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-20 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-19 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-18 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-15 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-14 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-13 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-12 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-11 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-08 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-07 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-06 | C+ | 2/5 | 3/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-05 | C+ | 2/5 | 3/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-04 | C+ | 2/5 | 3/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-01 | C+ | 2/5 | 3/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-30 | C+ | 2/5 | 3/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-29 | C+ | 2/5 | 3/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-28 | C+ | 2/5 | 3/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-27 | C+ | 2/5 | 3/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-24 | C+ | 2/5 | 3/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-23 | C+ | 2/5 | 3/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-22 | C+ | 2/5 | 3/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-21 | C | 2/5 | 3/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-20 | C | 2/5 | 3/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-17 | C | 2/5 | 3/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-16 | C | 2/5 | 3/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
-1.15M
OE per share TTM
-0.32
Owner's Yield
-0.54%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
11.7%
Ownership Overview
Ownership breakdown
At a glance
Institutional holders
8
Total invested
1.23M
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional ownership trend
From
To
13F snapshot — 2026 Q1
Investors holding
8
-2 vs prev Q
New positions
0
Closed positions
2
Increased
5
Reduced
1
Put/Call ratio
0.00
Calls held
—
Puts held
—
Top institutional holders
| # | Investor | Shares / Δ | Mkt value / Δ | Own% / Δ | Weight% / Δ | Avg px / Perf. | Hold / Status |
|---|---|---|---|---|---|---|---|
| 1 | GEODE CAPITAL MANAGEMENT, LLC | 60.2K +1.9K (+3.2%) | 463.8K -247.6K (-34.8%) | 0.09% +0.003 pp | 0.00% +0.000 pp | USD18.46 -58.3% | 3 qtrs — |
| 2 | CERITY PARTNERS LLC | 32.4K +— (+0.0%) | 249.5K -145.5K (-36.8%) | 0.05% +0.000 pp | 0.00% 0.000 pp | USD19.47 -60.5% | 3 qtrs — |
| 3 | CYPRESS CAPITAL MANAGEMENT LLC (WY) | 30.7K +3.2K (+11.4%) | 236.3K -99.4K (-29.6%) | 0.05% +0.005 pp | 0.22% -0.093 pp | USD18.26 -57.8% | 3 qtrs — |
| 4 | CITADEL ADVISORS LLC | 19.5K +7.9K (+68.4%) | 149.8K +9.0K (+6.4%) | 0.03% +0.012 pp | 0.00% +0.000 pp | USD10.37 -25.7% | 2 qtrs — |
| 5 | UBS GROUP AG | 11.6K +4.4K (+61.7%) | 89.5K +1.9K (+2.1%) | 0.02% +0.007 pp | 0.00% +0.000 pp | USD14.98 -48.6% | 3 qtrs — |
| 6 | WOLVERINE ASSET MANAGEMENT LLC | 4.9K +2.4K (+94.2%) | 37.6K +7.0K (+22.7%) | 0.01% +0.004 pp | 0.00% +0.000 pp | USD10.01 -23.1% | 2 qtrs — |
| 7 | MORGAN STANLEY | 223.00 -76.0 (-25.4%) | 1.7K -1.9K (-52.9%) | 0.00% 0.000 pp | 0.00% +0.000 pp | USD19.47 -60.5% | 3 qtrs — |
| 8 | FMR LLC | 1.00 +— (+0.0%) | 8.00 -4.0 (-33.3%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD19.00 -59.5% | 3 qtrs — |
| 9 | BANK OF AMERICA CORP /DE/ | — -5.0 (-100.0%) | — -61.0 (-100.0%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD— | 2 qtrs SOLD |
| 10 | CITIGROUP INC | — -1.7K (-100.0%) | — -20.8K (-100.0%) | 0.00% -0.003 pp | 0.00% +0.000 pp | USD— | 2 qtrs SOLD |
Ownership breakdown by holder
ETF Ownership
Top ETFs holding this stock
Held by 1 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Fidelity Nasdaq Composite Index ETF ONEQ | 0.00% | 50.9K | 0.21% |
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
0.00
Bearish
Buys
6
Sells
0
Shares acquired
12.5K
Shares disposed
—
Cash buys
—
Cash sales
—
Net activity
+12,486
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-03-31 | Lu Shao-Ta | Director | M-Exempt | A | Restricted Share Units | 2,081 | 0.00 | — | 0 | D | ↗ |
| 2026-03-31 | Chang Kochi | Director | M-Exempt | A | Restricted Share Units | 2,081 | 0.00 | — | 0 | D | ↗ |
| 2026-03-18 | Zhang Bo-Xiang | Director / Officer | — | — | Ordinary Shares | 0 | 0.00 | — | 31,141 | D | ↗ |
| 2026-03-18 | Shen Ethan PhD | Director / Officer | — | — | Ordinary Shares | 0 | 0.00 | — | 11,224,153 | D | ↗ |
| 2026-03-18 | Lu Shao-Ta | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2026-03-18 | Lee Jerry Yin-Chia | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2026-03-18 | Hen Man Edmund | Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2026-03-18 | Chang Kochi | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
Executive team
Top executives
EBIT / Employee
-13.2K
Shares Outstanding
70.83M
Executive compensation
Executive compensation (annual)
Executive compensation not available.
CEO compensation breakdown
No CEO compensation history available.
Proxy statements
Proxy statements (DEF 14A)
No proxy statements available for this company yet.
Recent SEC filings
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Benjamin Zhang | Chief Medical Officer & Director | — | male |
| Edmund Hen | Chief Financial Officer | — | male |
| Ethan Shen | CEO & Chairman | — | male |
ESG Score History
No data available for this company.
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for YDES
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
